UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Tumor mutational burden is predictive of response to immune checkpoint inhibitors in MSI-high metastatic colorectal cancer

Annals of oncology, 2019-07, Vol.30 (7), p.1096-1103

2019

Volltextzugriff (PDF)

Safety and clinical activity of atezolizumab in head and neck cancer: results from a phase I trial

Annals of oncology, 2018-11, Vol.29 (11), p.2247-2253

2018

Volltextzugriff (PDF)

Cabozantinib in hepatocellular carcinoma: results of a phase 2 placebo-controlled randomized discontinuation study

Annals of oncology, 2017-03, Vol.28 (3), p.528-534

2017

Volltextzugriff (PDF)

Ramucirumab combined with FOLFOX as front-line therapy for advanced esophageal, gastroesophageal junction, or gastric adenocarcinoma: a randomized, double-blind, multicenter Phase II trial

Annals of oncology, 2016-12, Vol.27 (12), p.2196-2203

2016

Volltextzugriff (PDF)

Phase 3 (COSMIC-312) study of cabozantinib in combination with atezolizumab vs sorafenib in patients with advanced hepatocellular carcinoma (aHCC) who have not received previous systemic anticancer therapy

Annals of oncology, 2019-07, Vol.30, p.iv65-iv66

2019

Volltextzugriff (PDF)

Ramucirumab combined with FOLFOX as front-line therapy for advanced esophageal, gastroesophageal junction, or gastric adenocarcinoma: a randomized, double-blind, multicenter Phase II trial

Annals of oncology, 2019-12, Vol.30 (12), p.2016-2016

2019

Volltextzugriff (PDF)

Right ventricular acrylic cement embolism: late complication of percutaneous vertebroplasty

Heart (British Cardiac Society), 2009-02, Vol.95 (4), p.275-275

2009

Volltextzugriff (PDF)

215 Using ALK IHC test to identify potential responders to ALK inhibitors outside of NSCLC

European journal of cancer (1990), 2015-09, Vol.51, p.S32-S32

2015

Volltextzugriff (PDF)

A phase Ib/II dose expansion study of subcutaneous sasanlimab in patients with locally advanced or metastatic non-small-cell lung cancer and urothelial carcinoma

ESMO open, 2023-08, Vol.8 (4), p.101589-101589, Article 101589

2023

Volltextzugriff (PDF)

Phase 1b/2 trial of taladegib (LY2940680), a Hh/Smo inhibitor, in combination with carboplatin and etoposide followed by taladegib maintenance in extensive-stage small-cell lung cancer

European journal of cancer (1990), 2016-12, Vol.69, p.S131-S132

2016

Volltextzugriff (PDF)

Efficacy and Safety of Onartuzumab in Combination With First-Line Bevacizumab- or Pemetrexed-Based Chemotherapy Regimens in Advanced Nonsquamous Non-Small Cell Lung Cancer (nsNSCLC): Results From a Phase 2, Placebo-Controlled Study (GO27821)

International journal of radiation oncology, biology, physics, 2014-11, Vol.90 (5), p.S37-S38

2014

Volltextzugriff (PDF)

14LBA Atezolizumab monotherapy vs docetaxel in 2L/3L non-small cell lung cancer: Primary analyses for efficacy, safety and predictive biomarkers from a randomized phase II study (POPLAR)

European journal of cancer (1990), 2015-09, Vol.51, p.S716-S717

2015

Volltextzugriff (PDF)

Efficacy and Safety Results From a Phase 2, Placebo-Controlled Study of Onartuzumab Plus First-Line Platinum-Doublet Chemotherapy in Advanced Squamous-Cell Non-Small Cell Lung Cancer (sq NSCLC)

International journal of radiation oncology, biology, physics, 2014-11, Vol.90 (5), p.S37-S37

2014

Volltextzugriff (PDF)

P-134 EV-202: An open-label, multicenter, phase 2 study of enfortumab vedotin in patients with previously treated locally advanced or metastatic solid tumors, including multiple gastroesophageal cancer cohorts

Annals of oncology, 2022-06, Vol.33, p.S298

2022

Volltextzugriff (PDF)

P-95 EV-202: An open-label, multicenter, phase 2 study of enfortumab vedotin in patients with previously treated locally advanced or metastatic solid tumors, including upper gastrointestinal cancers

Annals of oncology, 2021-07, Vol.32, p.S130

2021

Volltextzugriff (PDF)

Successful treatment of Erdheim-Chester disease, a non–Langerhans-cell histiocytosis, with interferon-α

Blood, 2005-11, Vol.106 (9), p.2992-2994

2005

Volltextzugriff (PDF)

Pain and Terminal Delirium Research in the Elderly

Clinics in geriatric medicine, 2005-02, Vol.21 (1), p.93-119

2005

Volltextzugriff (PDF)

P47.02 EV-202: Phase 2 Study of Enfortumab Vedotin for Previously Treated Advanced Solid Tumors Including Non-Small Cell Lung Cancer

Journal of thoracic oncology, 2021-10, Vol.16 (10), p.S1096-S1097

2021

Volltextzugriff (PDF)

Real-world comparative effectiveness analysis of second-line (2L) nab-paclitaxel (nab-P) vs eribulin (Erib) in patients (Pts) with metastatic breast cancer (MBC)

Annals of oncology, 2016-10, Vol.27, p.vi353-vi353

2016

Volltextzugriff (PDF)

Real-world comparative effectiveness analysis of second-line (2L) nab-paclitaxel (nab-P) vs paclitaxel (Pac) in patients (Pts) with metastatic breast cancer (MBC)

Annals of oncology, 2016-10, Vol.27, p.vi353-vi353

2016

Volltextzugriff (PDF)

P-238Phase 3 (COSMIC-312) study of cabozantinib in combination with atezolizumab vs sorafenib in patients with advanced hepatocellular carcinoma (aHCC) who have not received previous systemic anticancer therapy

Annals of oncology, 2019-07, Vol.30 (Supplement_4)

2019

Volltextzugriff (PDF)

Liposome-encapsulated curcumin : In vitro and in vivo effects on proliferation, apoptosis, signaling, and angiogenesis

Cancer, 2005-09, Vol.104 (6), p.1322-1331

2005

Volltextzugriff (PDF)

Comparative effectiveness and resource utilization of nab -paclitaxel plus gemcitabine vs FOLFIRINOX or gemcitabine for the first-line treatment of metastatic pancreatic adenocarcinoma in a US community setting

Cancer management and research, 2017-01, Vol.9, p.141-148

2017

Volltextzugriff (PDF)

555TiP A first-in-human trial of the integrin beta-6-targeted antibody–drug conjugate, SGN-B6A, in patients with advanced solid tumors

Annals of oncology, 2021-09, Vol.32, p.S613-S613

2021

Volltextzugriff (PDF)

833TiP - Phase III (COSMIC-312) study of cabozantinib (C) in combination with atezolizumab (A) vs sorafenib (S) in patients (pts) with advanced hepatocellular carcinoma (aHCC) who have not received previous systemic anticancer therapy

Annals of oncology, 2019-10, Vol.30, p.v320-v320

2019

Volltextzugriff (PDF)

1 – 25 von 93

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(93)
Mit Volltextzugriff
(82)

Publikationsform

Artikel
(91)
Tagungsberichte
(2)

Sprache

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(27)
Science & Technology
(27)
Humans
(18)
Oncology
(18)
Male
(12)
Female
(11)
Aged
(10)
Middle Aged
(10)
Adult
(8)
Patients
(7)
Metastasis
(6)
Tumors
(6)
Biological And Medical Sciences
(5)
Cancer Therapies
(5)
Chemotherapy
(5)
Hematology, Oncology And Palliative Medicine
(5)
Medical Sciences
(5)
Clinical Trials
(4)
Drug Dosages
(4)
Hematology
(4)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Tumor mutational burden is predictive of response to immune checkpoint inhibitors in MSI-high metastatic colorectal cancer

Safety and clinical activity of atezolizumab in head and neck cancer: results from a phase I trial

Cabozantinib in hepatocellular carcinoma: results of a phase 2 placebo-controlled randomized discontinuation study

Ramucirumab combined with FOLFOX as front-line therapy for advanced esophageal, gastroesophageal junction, or gastric adenocarcinoma: a randomized, double-blind, multicenter Phase II trial

Phase 3 (COSMIC-312) study of cabozantinib in combination with atezolizumab vs sorafenib in patients with advanced hepatocellular carcinoma (aHCC) who have not received previous systemic anticancer therapy

Ramucirumab combined with FOLFOX as front-line therapy for advanced esophageal, gastroesophageal junction, or gastric adenocarcinoma: a randomized, double-blind, multicenter Phase II trial

Right ventricular acrylic cement embolism: late complication of percutaneous vertebroplasty

215 Using ALK IHC test to identify potential responders to ALK inhibitors outside of NSCLC

A phase Ib/II dose expansion study of subcutaneous sasanlimab in patients with locally advanced or metastatic non-small-cell lung cancer and urothelial carcinoma

Phase 1b/2 trial of taladegib (LY2940680), a Hh/Smo inhibitor, in combination with carboplatin and etoposide followed by taladegib maintenance in extensive-stage small-cell lung cancer

Efficacy and Safety of Onartuzumab in Combination With First-Line Bevacizumab- or Pemetrexed-Based Chemotherapy Regimens in Advanced Nonsquamous Non-Small Cell Lung Cancer (nsNSCLC): Results From a Phase 2, Placebo-Controlled Study (GO27821)

14LBA Atezolizumab monotherapy vs docetaxel in 2L/3L non-small cell lung cancer: Primary analyses for efficacy, safety and predictive biomarkers from a randomized phase II study (POPLAR)

Efficacy and Safety Results From a Phase 2, Placebo-Controlled Study of Onartuzumab Plus First-Line Platinum-Doublet Chemotherapy in Advanced Squamous-Cell Non-Small Cell Lung Cancer (sq NSCLC)

P-134 EV-202: An open-label, multicenter, phase 2 study of enfortumab vedotin in patients with previously treated locally advanced or metastatic solid tumors, including multiple gastroesophageal cancer cohorts

P-95 EV-202: An open-label, multicenter, phase 2 study of enfortumab vedotin in patients with previously treated locally advanced or metastatic solid tumors, including upper gastrointestinal cancers

Successful treatment of Erdheim-Chester disease, a non–Langerhans-cell histiocytosis, with interferon-α

Pain and Terminal Delirium Research in the Elderly

P47.02 EV-202: Phase 2 Study of Enfortumab Vedotin for Previously Treated Advanced Solid Tumors Including Non-Small Cell Lung Cancer

Real-world comparative effectiveness analysis of second-line (2L) nab-paclitaxel (nab-P) vs eribulin (Erib) in patients (Pts) with metastatic breast cancer (MBC)

Real-world comparative effectiveness analysis of second-line (2L) nab-paclitaxel (nab-P) vs paclitaxel (Pac) in patients (Pts) with metastatic breast cancer (MBC)

P-238Phase 3 (COSMIC-312) study of cabozantinib in combination with atezolizumab vs sorafenib in patients with advanced hepatocellular carcinoma (aHCC) who have not received previous systemic anticancer therapy

Liposome-encapsulated curcumin : In vitro and in vivo effects on proliferation, apoptosis, signaling, and angiogenesis

Comparative effectiveness and resource utilization of nab -paclitaxel plus gemcitabine vs FOLFIRINOX or gemcitabine for the first-line treatment of metastatic pancreatic adenocarcinoma in a US community setting

555TiP A first-in-human trial of the integrin beta-6-targeted antibody–drug conjugate, SGN-B6A, in patients with advanced solid tumors

833TiP - Phase III (COSMIC-312) study of cabozantinib (C) in combination with atezolizumab (A) vs sorafenib (S) in patients (pts) with advanced hepatocellular carcinoma (aHCC) who have not received previous systemic anticancer therapy

Suchergebnisse filtern